Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: A 96-week pilot trial in treatment-naive patients

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 6, 2009, Pages 379-384

  Landman, R ^a   Poupard, M ^a   Diallo, M ^b   Ngom Gueye, N F ^b   Diakhate, N ^b   Ndiaye, B ^b   Toure Kane, C ^c   Trylesinski, A ^d   Diop, H ^c   Mboup, S ^d   Koita Fall, M B ^b   Delaporte, E ^e   Benalycherif, A ^a   Girard, P M ^a,f   Sow, P S ^b  

^a BICHAT HOSPITAL   (France)

^b Centre Hospitalier Universitaire Dakar   (Senegal)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d Gilead Sciences   (France)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

efavirenz; emtricitabine; first line treatment; HAART; HIV 1; safety; sub Saharan Africa; tenofivir

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; EFAVIRENZ; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SENEGAL;

ADENINE; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHONIC ACIDS; PILOT PROJECTS; QUALITY OF LIFE; RNA, VIRAL; SENEGAL;

EID: 77951231574     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109709344352     Document Type: Article

References (20)

1. Merson MH The HIV-AIDS pandemic at 25-the global response. N Engl J Med. 2006 ; 354 (23). 2414-2417. (Pubitemid 43855044)
2. Van Damme W., Kober K., Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS. 2006 ; 20 (5). 653-656. (Pubitemid 43884291)
3. Ferradini L., Jeannin A., Pinoges L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006 ; 367 (9519). 1335-1342.
4. Laurent C., Ngom Gueye NF, Ndour CT, et al., and the ANRS 1215/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005 ; 38 (1). 14-17. (Pubitemid 40094112)
5. Danel C., Moh R., Anzian A., et al. Tolerability and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006 ; 42 (1). 29-35. (Pubitemid 43947943)
6. Lyseng-Williamson KA, Reynolds NA, Plosker GL Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005 ; 65 (3). 413-432. (Pubitemid 40227461)
7. Gallant JE, DeJesus E., Arribas JR, et al., for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006 ; 354 (3). 251-260. (Pubitemid 43113030)
8. WHO Antiretroviral therapy for HIV infection in adults et adolescents in resource limited settings: toward universal access. Recommendations for a public health approach. http://www.who.int. Accessed September 7th, 2009.
9. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16 (1). 31-41.
10. Landman R., Schiemann R., Thiam S., et al., and the Imea 011/ANRS 12-04 Study Group. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1-infected adults in Senegal. AIDS. 2003 ; 17 (7). 1017-1022. (Pubitemid 36549713)
11. Etard JF, Ndiaye I., Thierry-Mieg M., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006 ; 20 (8). 1181-1189. (Pubitemid 43786107)
12. Riddler SA, Haubrich R., DiRienzo AG, et al., for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 ; 358 (20). 2095-2106. (Pubitemid 351679596)
13. Mauss S., Berger F., Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005 ; 19 (1). 93-95. (Pubitemid 40111024)
14. Gallant JE, Parish MA, Keruly JC, Moore RD Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005 ; 40 (8). 1194-1198. (Pubitemid 40490248)
15. Izzedine H., Hulot JS, Vittecoq D., et al., for the Study 903 Team. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral- naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005 ; 20 (4). 743-746. (Pubitemid 40520651)
16. Malik A., Abraham P., Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005 ; 51 (2). E61 - E65.
17. Nelson MR, Katlama C., Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007 ; 21 (10). 1273-1281. (Pubitemid 46883481)
18. Reid AJC Glomerular dysfunction and associated risk factors following initiation of ART in Africa: a subanalysis in the DART Trial [oral presentation]. Paper presented at: 16th International AIDS Conference ; August 13-18, 2006 ; Toronto, Canada.
19. Mwango A., Gigant M., Mulenga L., et al. First-line Tenofovir ART: Zambia. Paper presented at: 16th Conference on Retroviruses and Opportunistic infections; February 8-11, 2009 ; Montreal, Canada.
20. Beck EJ, Vitoria M., Mandalia S., Crowley S., Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS. 2006 ; 20 (11). 1497-1502. (Pubitemid 44100210)